ACCESSWIRE
25 Jan 2023, 23:05 GMT+10
NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ('Nascent Biotech', 'Nascent', or the 'Company'), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ('PTB') as a treatment for Brain Cancer.
The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the 'FDA') for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab.
PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
About Nascent Biotech
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available.
For further information please visit our website www.nascentbiotech.com.
Safe Harbor: Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Corporate Contact
Sean Carrick | President | CEO | Nascent Biotech, Inc.
772.713.0541 Cell | [email protected]
Public Relations
EDM Media, LLC
https://edm.media
SOURCE: Nascent Biotech Inc.
Get a daily dose of Salt Lake City Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Salt Lake City Sun.
More InformationNEW YORK, New York - U.S. stocks posted a decent rally on Thursday with all the major indices making good ...
FREMONT, California: Neuralink, Elon Musk's brain implant company, has approached the Barrow Neurological Institute, one of the largest US neurosurgery ...
BRUSSELS, Belgium: The energy ministers of European Union member countries have approved a landmark law to end sales of new ...
BEIJING, China: After more than a year of self-imposed exile overseas, Alibaba founder Jack Ma has returned to China, allegedly ...
NEW YORK, New York - U.S. stocks and the dollar made solid gains on Wednesday as banking sector fears continued ...
NEW YORK CITY, New York: In a legal filing, Twitter announced that parts of its source code - the fundamental ...
ROLLING FORK, Mississippi: A powerful tornado has struck Mississippi, killing at least 25 people, injuring dozens, flattening entire blocks and ...
Colorado Rockies closer Daniel Bard will open the season on the injured list, with right-hander Jake Bird taking his spot ...
The final report of the Mass Casualty Commission investigating the April 2020 mass shooting in Nova Scotia that left 22 ...
Donald Trump has been indicted by a Manhattan grand jury over hush money paid to porn star Stormy Daniels, becoming ...
Just three points out of first place in the Central Division with eight games remaining, the Dallas Stars will start ...
Former US president Donald Trump has been indicted by a Manhattan grand jury on Thursday for his role in allegedly ...